Platelet BioGenesis Receives $56 Million Contract from BARDA

01Oct

Platelet BioGenesis Receives $56 Million Contract from BARDA

Portfolio News
Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure. Read more >>

Share this post

Related Posts

01Dec

Myomo, Inc. Announces Pricing of Public Offering

Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that it has priced an underwritten public... read more
23Jun

Myomo Resumes Fitting MyoPro Patients and Deliveries as States Begin to Re-Open after COVID-19 Shutdowns

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,... read more
18Mar

Mike Baker Joins Pixability’s Board of Directors

Pixability, the leading provider of software and insights for video advertising on YouTube and Connected TV, today announced that Mike... read more
09Jan

All Hands on Tech – eSight electronic assisted glasses enhance eyesight

Toronto-based eSight has been making its device that helps legally-blind people see, using a visor that relays an enhanced camera... read more
20Dec

Walmart’s 2016 holiday videos on YouTube have earned over 75M views – Insight from Pixability

Walmart’s push on YouTube this holiday season is paying off, earning the brand more than 75 million video views for... read more
24Nov

Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers

Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and... read more
14Feb

Windgap Medical Appoints Aaron Mann as CEO, Michael Samar as CFO

Windgap Medical announced today it has appointed Aaron Mann as the company's Chief Executive Officer and Michael Samar as the... read more
01Aug

Myomo, Inc. Obtains CE Mark Approval for MyoPro®

Myomo, Inc. (NYSE MKT:MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it has obtained... read more
31Dec

Knipbio $2.00 million Fundraising

Knipbio, Inc., Corporation just had published form D about $2.00 million equity financing. This is a new filing. Knipbio was... read more
13Feb

Hoth Therapeutics Announces Positive Preliminary, Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

The study conducted in partnership with Zylö Therapeutics confirmed AEA-loaded in Z-pods™ provides an actual reduction in lesion score. Read... read more